Achilles Therapeutics PLC ADR (ACHL)vsEli Lilly and Company (LLY)
ACHL
Achilles Therapeutics PLC ADR
$1.48
0.00%
HEALTHCARE · Cap: $63.22M
LLY
Eli Lilly and Company
$1,354.49
-0.79%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).
ACHL
Avoid32
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACHL
The strongest argument for ACHL centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : ACHL
The primary concerns for ACHL are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
ACHL profiles as a value stock while LLY is a growth play — different risk/reward profiles.
ACHL carries more volatility with a beta of 1.25 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 32/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Achilles Therapeutics PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?